atrasentan experimental drug studied treatment various types including nonsmall cell lung also investigated therapy diabetic kidney disease atrasentan failed phase trial prostate cancer patients unresponsive hormone second trial confirmed endothelin receptor antagonist selective subtype eta drugs type sitaxentan ambrisentan exploit vasoconstrictive properties endothelin mainly used treatment pulmonary arterial hypertension atrasentan blocks endothelin induced cell proliferationcitation needed april de zeeuw et al showed mg mg atrasentan reduced urinary albumin respectively modest side effects patients also decreased home blood pressures change office readings decrease total cholesterol ldl patients mg dose group increased weight gain presumably due increased edema withdraw study placebo mg dose reductions proteinuria associated beneficial patient outcomes diabetic kidney disease interventions accepted endpoint fdacitation needed sonar initiated determine atrasentan reduces kidney failure diabetic kidney httpsenwikipediaorgwikiatrasentan